Suppression of Energy Metabolism in Cancer Cells with Nutrient-Sensing Nanodrugs
Source abstract
Abstract
Uncontrolled growth of tumor cells is highly dependent on the energy metabolism. Fasting-mimicking diet (FMD) is a low-calorie, low-protein, low-sugar diet representing a promising strategy for cancer treatment. However, triglyceride stored in adipose tissue is hydrolyzed into free fatty acids and glycerol for energy supply during FMD treatment. Herein, we design a nutrient-sensing nanodrug, VFETX, which is self-assembled with vitamin B1 (VB1), ferrous ions, and etomoxir (ETX). FMD treatment upregulate the expression of VB1 transporters on tumor cells, thereby increasing cellular uptake and tumor accumulation of VFETX. Importantly, treatments of VFETX and FMD synergistically inhibit the energy metabolism in tumor cells and subsequently markedly enhance cytotoxicity of ETX. As a result, VFETX nanodrugs efficiently inhibit the growth of two tumor models in vivo without obvious side effects. This study demonstrates the potential of FMD-assisted nutrient-sensing nanodrugs for cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Diet and metabolism studies · Cancer, Hypoxia, and Metabolism · Epigenetics and DNA Methylation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, School of Science, Tianjin University, Tianjin 300354, China
CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China
University of Chinese Academy of Sciences, Beijing 100049, China
Funding
National Natural Science Foundation of China
References (30)
Show source-provided references
1. 10.1016/j.biocel.2014.12.00810.1016/j.biocel.2014.12.008 ↗
2. 10.1126/sciadv.160020010.1126/sciadv.1600200 ↗
3. 10.1038/s42255-020-00317-z10.1038/s42255-020-00317-z ↗
4. 10.1038/s41568-021-00378-610.1038/s41568-021-00378-6 ↗
5. 10.1126/scitranslmed.300329310.1126/scitranslmed.3003293 ↗
6. 10.1016/j.cmet.2013.12.00810.1016/j.cmet.2013.12.008 ↗
7. 10.1016/j.ccell.2016.06.00510.1016/j.ccell.2016.06.005 ↗
8. 10.1038/s41586-020-2957-610.1038/s41586-020-2957-6 ↗
9. 10.1038/s41568-018-0061-010.1038/s41568-018-0061-0 ↗
10. 10.1016/j.devcel.2015.01.02910.1016/j.devcel.2015.01.029 ↗
11. 10.1016/j.canlet.2018.08.00610.1016/j.canlet.2018.08.006 ↗
12. 10.1038/nrc348310.1038/nrc3483 ↗
13. 10.1021/jm100809g10.1021/jm100809g ↗
14. 10.1007/s13277-016-5382-610.1007/s13277-016-5382-6 ↗
15. 10.1038/s41598-018-24676-610.1038/s41598-018-24676-6 ↗
16. 10.3390/cancers1210283710.3390/cancers12102837 ↗
17. 10.3389/fphar.2018.0002710.3389/fphar.2018.00027 ↗
18. 10.1021/acs.nanolett.9b0002110.1021/acs.nanolett.9b00021 ↗
19. 10.1021/acs.nanolett.0c0197310.1021/acs.nanolett.0c01973 ↗
20. 10.1021/bi401618y10.1021/bi401618y ↗
21. 10.3945/an.116.01397910.3945/an.116.013979 ↗
22. 10.1002/anie.20181073510.1002/anie.201810735 ↗
23. 10.1002/anie.20181008710.1002/anie.201810087 ↗
24. 10.1002/open.20190036310.1002/open.201900363 ↗
25. 10.1002/adfm.20160333610.1002/adfm.201603336 ↗
26. 10.1021/acs.nanolett.0c0262210.1021/acs.nanolett.0c02622 ↗
27. 10.1152/ajpgi.00484.201110.1152/ajpgi.00484.2011 ↗
28. 10.1016/j.plipres.2013.08.00510.1016/j.plipres.2013.08.005 ↗
29. 10.1038/s41392-020-00326-010.1038/s41392-020-00326-0 ↗
30. 10.1038/s41419-018-0313-710.1038/s41419-018-0313-7 ↗